Key statistics
As of last trade Elicio Therapeutics Inc (9HA:FRA) traded at 7.80, -23.53% below its 52-week high of 10.20, set on Aug 19, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 7.75 |
|---|---|
| High | 7.80 |
| Low | 7.75 |
| Bid | 7.05 |
| Offer | 7.40 |
| Previous close | 6.80 |
| Average volume | 365.89 |
|---|---|
| Shares outstanding | 17.49m |
| Free float | 11.06m |
| P/E (TTM) | -- |
| Market cap | 166.33m USD |
| EPS (TTM) | -3.15 USD |
Data delayed at least 15 minutes, as of Feb 10 2026 14:25 GMT.
More ▼
Announcements
- Elicio Therapeutics Reports Inducement Grants
- Elicio Therapeutics Reports Inducement Grants
- Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial
- Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
- Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
- Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC
- Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting
- Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial
- Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
- Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial
More ▼
